Science Awards for Allergy 2025: Call for Applications
The Stallergenes Greer Foundation is pleased to announce the launch of the 2025 edition of its Science Awards for Allergy, an initiative dedicated to recognising outstanding contributions to allergy research and environmental health initiatives.
Building on the success of the previous edition, the 2025 Science Awards for Allergy focus on innovation, patient empowerment, and solutions which aim to improve quality of life for individuals with allergies through personalised solutions, cutting-edge research, and comprehensive care approaches.
The foundation will honour exceptional contributions by awarding a total of €150,000 in two categories:
- Innovation in Allergy Treatment Award
The award recognises cutting-edge research with clinical relevance in the field of allergy. It will support projects with practical outcomes and applications, which deepen knowledge of allergy treatments and inspire young researchers and clinicians. The award is expected to facilitate the implementation of innovative approaches in allergy care particularly in the areas of prevention, intervention and research. - Patient Commitment Award
This award recognises projects which integrate the perspectives of patients with allergies, as well as those of their family, foster knowledge of allergic diseases and treatments, and develop the understanding of unmet needs to improve allergy care for all. The work must contribute to better understanding, preventing and treating respiratory or food allergy diseases.
Submission Period: January 6, 2025, to November 28, 2025 (11:59 PM CET).
Eligibility: Open to individuals, researchers, medical doctors, non-profit research laboratories, associations, and organisations engaged in allergy research or patient-centered initiatives. Candidates should demonstrate innovation, impact, and practical outcomes in their work.
Rules and regulations: Detailed information about eligibility, criteria, and the application process can be found on the foundation’s website: www.stallergenesgreer-foundation.org
About the Stallergenes Greer Foundation
The Stallergenes Greer Foundation is a non-profit organisation focused on creating healthier futures for all. Guided by the One Health initiative, the foundation promotes multidisciplinary collaboration to improve the health of people, animals, and the environment.
The foundation, placed under the aegis of the Fondation de France, is philanthropically dedicated to three focus areas:
- Advancing scientific research to bolster innovation and precision medicine.
- Supporting academic initiatives to further develop future generations of allergy healthcare professionals.
- Engaging in climate action and environmental protection to progress the prevention and treatment of allergies.
The Stallergenes Greer Foundation is governed by a Board of Trustees which brings together the Managing Board and the Scientific Board. The Scientific Board is composed of four independent members:
- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France);
- Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, Vatican City (Italy);
- Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon);
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)
About Fondation de France
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity and translate them into effective actions of general interest. With close to 1,000 hosted foundations, the Fondation de France supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
For further details, visit www.fondationdefrance.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106391220/en/
Contacts
Stallergenes Greer Foundation
Catherine Kress
Secretary General
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces $43 Million Contract Award in the Middle East Region10.1.2025 16:23:00 EET | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced it has received a formal letter of award for a development project located in the GCC region. Perma-Pipe will provide thermal insulation, anti-corrosion coatings, and other services from its Abu Dhabi facility. Project commencement is expected to begin in the third quarter of 2025. The value of this project is estimated to exceed $43 million. This project will utilize Perma-Pipe’s anti-corrosion coatings capabilities, fabrication, and the TRACE-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “This award follows the successful execution of numerous development projects in the region. Our differentiated coating solutions have proven to be well-suited for technically challenging projects. We would like to thank our customers for this significant award.” David Mansfield, President and CEO
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions10.1.2025 16:00:00 EET | Press release
Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings. Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally. A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices. Lenovo Retail Robotics with Yunji offer
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration10.1.2025 15:00:00 EET | Press release
RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligi
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore10.1.2025 14:30:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110168811/en/ Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and deve
Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 14:01:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom